Oncology

Your Article Summary

See Latest Articles

Antiangiogenic strategies for treatment of malignant gliomas
Neurotherapeutics, 07/01/09

Chi AS et al. - A review of antiangiogenic strategies for treatment of malignant gliomas (MG) summarizes clinical experience with antiangiogenic therapy in MG pts, major issues for use and development of these agents, and strategies based on initial gains seen with antiangiogenic agents.

• Review of antiangiogenic strategies for treatment of MG

• Studies are ongoing for numerous antiangiogenic agents with diverse mechanisms of action in treatment of GBM pts
• Early clinical trials suggest that antiangiogenic drugs, which target blood vessels of these highly angiogenic tumors, may have clinical benefit in GBM pts
• Antiangiogenic agents have potent antiedema and steroid-sparing effects; emerging data suggest modest improvement in progression-free survival
• Post-treatment with antiangiogenic agents, a major challenge is interpretation of radiographic changes
• Reliable radiographic and biologic markers are lacking to predict which pts benefit from treatment and accurately indicate response and progression during therapy
• Most pts treated with antiangiogenic drugs eventually progress

Today in Neurologic Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Primary central nervous system lymphoma: an update
Current Opinion in Oncology, 10/12/09

Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial
The Lancet Oncology - Online First, 10/07/09

Medulloblastoma in childhood: revisiting intrathecal therapy in infants and children
Cancer Chemotherapy and Pharmacology, 10/29/09

See All of Neurologic Oncology